By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Regeneron Pharmaceuticals, Inc. 

777 Old Saw Mill River Road

Tarrytown  New York  10591  U.S.A.
Phone: 914-847-7000 Fax: n/a


SEARCH JOBS



Known for its scientific and operational excellence, Regeneron is a leading science-based biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron markets medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including hypercholesterolemia, oncology, rheumatoid arthritis, allergic asthma, and atopic dermatitis.

Visit our website – www.regeneron.com
Check out our openings – www.careers.regeneron


Key Statistics


Email:
Ownership: Public

Web Site: Regeneron
Employees: 2300+
Symbol: REGN
 



Industry
Biotechnology


Collaborations

Sanofi US 

Bayer 

Geisinger Health System  Collaboration with Regeneron Genetics Center LLC, wholly-owned subsidiary of Regeneron.

Avalanche Biotechnologies 





Company News
Regeneron (REGN) Release: EYLEA (aflibercept) Injection Receives FDA Approval For The Treatment Of Diabetic Retinopathy In Patients With Diabetic Macular Edema (DME) 3/25/2015 9:16:56 AM
Filing Shows Regeneron (REGN) Stopped Paying CEO and CSO's Club Membership Fees 3/23/2015 6:05:01 AM
Sanofi (SAN.PA), Regeneron (REGN): 18-Month Results Of ODYSSEY LONG TERM Trial With Praluent (Alirocumab) Published In The New England Journal of Medicine 3/16/2015 6:01:28 AM
New Cholesterol Drugs From Amgen (AMGN), Sanofi (SAN.PA), Regeneron (REGN) Cut Heart Risks in Half But Questions Remain 3/16/2015 5:59:13 AM
Regeneron (REGN) Release: EYLEA (aflibercept) Injection Receives EU Approval For The Treatment Of Visual Impairment Due To Macular Edema Secondary To Retinal Vein Occlusion 2/26/2015 7:03:18 AM
Regeneron (REGN) Release: NIH-Sponsored Comparative Effectiveness Trial In Diabetic Macular Edema Shows EYLEA (Aflibercept) Injection Demonstrated Significantly Greater Gains In Visual Acuity Than Both Bevacizumab And Ranibizumab 2/19/2015 6:12:29 AM
Regeneron (REGN)'s Eylea Beats Genentech (RHHBY) in Rare Face Off Over Some Vision Loss Cases 2/19/2015 6:11:14 AM
Regeneron (REGN) Release: New Results From Cholesterol Counts Show Most Americans Polled Do Not Know Their Bad Cholesterol (LDL-C) Levels 2/18/2015 10:52:25 AM
Regeneron (REGN) Announces Upcoming 2015 Investor Conference Presentations 2/13/2015 7:48:03 AM
Regeneron (REGN) Reports Fourth Quarter And Full Year 2014 Financial And Operating Results 2/10/2015 7:45:36 AM
12345678910...
//-->